摘要
目的分析载脂蛋白E基因(APOE)多态性预测年龄相关性黄斑变性(age-related macular degeneration,AMD)玻璃体内康柏西普注射疗效的价值。方法选取2016年10月～2018年4月于我院经FFA和OCT确诊的年龄相关性黄斑变性患者76眼作为研究对象。所有患眼均每月接受10 mg/mL康柏西普玻璃体内注射0.05 mL,注射后每月随访1次,连续注射3个月,比较注射前和注射后1、2、3个月患者的最佳视力(best corrected visual acuity,BCVA)、黄斑中心凹视网膜厚度(central macular thickness,CMT)以及不同APOE等位基因分型疗效。结果治疗前BCVA为(50.36±9.84),治疗后1、2、3个月的BCVA为(70.18±11.07)、(72.22±12.06)和(70.31±12.39),与治疗前相比均明显提高(P<0.05)。治疗前CMT为(465.23±79.82)μm,治疗后1、2、3个月的CMT为(268.31±94.13)μm、(259.21±82.09)μm和(259.42±81.35)μm,与治疗前相比均明显降低(P<0.05)。根据不同基因分型分析,与APOEε3相比,APOEε4和APOEε2型的患者BCVA明显较高,CMT明显较低(P均<0.05),而APOEε2和APOEε4型患者的BCVA和CMT无明显差异(P>0.05)。结论玻璃体内康柏西普注射疗效治疗年龄相关性黄斑变性疗效显著,APOEε4和APOEε2型的患者疗效更佳,APOE分型可为康柏西普治疗AMD提供指导。
Objective To analyze the value of apolipoprotein E gene (APOE) polymorphism in predicting the efficacy of intravitreal Conbercept injection in age-related macular degeneration(AMD). Methods A total of 76 eyes of age-related macular degeneration patients diagnosed by FFA and OCT in our hospital from October 2016 to April 2018 were selected as subjects. All eyes received a monthly injection of 10 mg/mL Conbercept intravitreal injection of 0.05 mL, followed by monthly injections for 3 months. The best corrected visual acuity (BCVA), central macular thickness (CMT) and different APOE allele genotyping effects before and at 1, 2, and 3 months after injection were compared. Results The BCVA before treatment was(50.36±9.84). The levels of BCVA at 1, 2, and 3 months after treatment were(70.18±11.07),(72.22±12.06) and (70.31±12.39), which were all significantly higher than those before treatment(P<0.05). The CMT before treatment was(465.23±79.82)μm. And the levels of CMT at 1, 2, and 3 months after treatment were(268.31±94.13)μm,(259.21±82.09)μm and (259.42±81.35)μm, which were significantly lower than those before treatment (P<0.05). According to different genotyping analysis, compared with that of patients with APOEε3, the BCVA was significantly higher and the CMT was significantly lower in patients with APOEε4 and APOEε2 (P<0.05). While there were no significant differences in BCVA and CMT between APOEε2 patients and APOEε4 patients (P>0.05). Conclusion The efficacy of intravitreal Conbercept injection in the treatment of age-related macular degeneration is significant. Patients with APOEε4 and APOEε2 have better efficacy. APOE typing can provide guidance for the treatment of AMD with Conbercept.
作者
邓吕红
谭钢
郑浩
唐九丰
DENG Lvhong;TAN Gang;ZHENG Hao;TANG Jiufeng(Department of Ophthalmology, the First Affiliated Hospital of Nanhua University, Hengyang 421001, China)
出处
《中国现代医生》
2019年第8期77-79,83,共4页
China Modern Doctor
基金
湖南省教育厅科研优秀青年项目(15B210)
